Although FLT3 activating mutations appear to be primarily restricted to myeloid leukemias in patients, wildtype FLT3 is known to be expressed in lymphoid precursors and is expressed at low levels in nearly 100% of B-cell ALLs, suggesting a role for the receptor in early B-cell development [16-18]. This evidence concerns the gene FLT3 and myeloid leukemia.